Search This Blog

Tuesday, June 10, 2025

Novo Nordisk starts new CagriSema weightloss drug trial

 Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential after disappointing data from two previous studies.

The Danish company made the announcement in an entry published on

"This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term," Novo Nordisk (NYSE:NVO) said in the entry.

The company had positioned CagriSema as a more potent successor to its blockbuster obesity shot Wegovy, boosting market expectations that its weight-loss potential was greater than that of U.S. drugmaker Eli Lilly (NYSE:LLY)’s rival drug Mounjaro.

But lower-than-expected weight loss shown with CagriSema in data the company published in December and March knocked shares and stoked worries that Lilly may be gaining an edge over Novo in the obesity drugs market.

Novo said in February it planned to begin a new trial of CagriSema by June and expected it to last longer than the original 68-week study because the data it published in December suggested additional weight loss could be achieved over a longer period of time.

https://www.investing.com/news/stock-market-news/novo-nordisk-starts-new-cagrisema-weightloss-drug-trial-4089275

Harrow stock wins William Blair's new Outperform (HROW)

 Harrow (HROW) stock earns an Outperform rating at William Blair after securing U.S. rights to Byqlovi, a post-surgical pain therapy.

https://seekingalpha.com/news/4456966-harrow-stock-wins-william-blairs-new-outperform

US 2nd-Largest Wine And Spirits Distributor Exits California Market Over Costs, Suppliers

 by Kimberly Hayek via The Epoch Times (emphasis ours),

Wine and spirits distributor Republic National Distributing Company (RNDC) is leaving the California market.

RNDC cited increasing costs and changes among suppliers as one of the reasons it has decided to stop operating in the state.

“This decision follows years of increasing costs, industry headwinds, and supplier shifts that have made it difficult to operate sustainably in the state,” its leadership said in an emailed statement to its customers on June 4. “We are incredibly proud of our California team and all of their hard work over the years. Please know that our commitment to you during this transition remains unwavering.”

RNDC has lost several significant distribution partnerships in California in recent years. The company’s announcement comes just months after two major suppliers, Tito’s Vodka and Jack Daniel’s maker Brown-Forman, departed from their California distribution relationship with RNDC in favor of its competitor, Reyes Beverage Group.

E. & J. Gallo Winery, which owns the High Noon brand, also ended its relationship with RNDC in the state in 2025, opting instead for Reyes Beverage Group.

In 2023, Sazerac ended its longtime relationship with RNDC in California. The bourbon and whiskey maker moved its brands including Buffalo Trace, Pappy Van Winkle, and Fireball Whisky, to the Reyes Beverage Group.

RNDC did not return a request for comment.

Other companies such as Chevron, Tesla, Oracle, and Hewlett Packard Enterprise, have in recent years moved their headquarters from California to states like Texas or Nevada. Unlike RNDC, which also plans to cease servicing the state, these companies continue to operate in California’s sizable economy.

RNDC joins a list of national companies—many of them insurance providers—that have fully exited the California market.

Farmers Direct Property and Casualty Insurance Company withdrew from the California homeowners insurance market in 2023. That same year, American National also announced it would stop offering homeowners insurance in the state, a move that affected more than 36,000 policies. In addition, Merastar Insurance stopped renewing homeowners and car insurance policies in California beginning in 2024.

Some other companies still operating in California have made moves to limit their operations in the state. State Farm and Allstate announced they would no longer be accepting new applications for homeowners insurance, citing rising costs and wildfire risks.

A Farmers Direct Property and Casualty Insurance spokesperson previously told The Epoch Times the company made its decision to increase efficiency and mitigate risk exposure.

Berkshire Hathaway’s AmGUARD, a division of the firm’s GUARD Insurance company, informed the California Department of Insurance in July 2023 of its plan to cancel the homeowners and personal umbrella policies it holds in the state, which followed through on two months later. AmGUARD’s notice came the same day that the small insurance firm Falls Lake Insurance submitted a letter indicating it would also be canceling policies in the state.

A 2022 report by the Hoover Institution found that 352 companies relocated from California to other states between 2018 to 2021, primarily due to the state’s high operating costs.

https://www.zerohedge.com/markets/nations-2nd-largest-wine-and-spirits-distributor-exits-california-market-over-costs

Fractyl Health, Bariendo sign non-binding LOI, to offer Revita nationwide

 Fractyl Health (GUTS) and Bariendo announced the signing of a non-binding Letter of Intent, LOI, to explore a future collaboration centered on Fractyl’s investigational Revita procedure as a durable off-ramp for weight maintenance following GLP-1 drug discontinuation. This agreement comes as Fractyl prepares for three key data readouts from its ongoing pivotal study of Revita: REVEAL-1 Cohort open-label data expected in June 2025; REMAIN-1 Midpoint Cohort data expected in the third quarter of 2025; and 6-month primary endpoint data from the REMAIN-1 Pivotal Cohort expected in the second half of 2026. Together, these clinical milestones are designed to demonstrate Revita’s potential to help maintain weight loss after GLP-1 discontinuation and inform its possible role in supporting durable metabolic outcomes. Bariendo brings to the partnership a scalable, physician-driven platform designed to deliver a holistic approach to obesity, including metabolic endoscopic solutions at the nation’s largest network of high-volume hospital and ambulatory endoscopy centers across the United States

https://www.tipranks.com/news/the-fly/fractyl-health-bariendo-sign-non-binding-loi-to-offer-revita-nationwide-thefly

Gelteq Accelerates US Growth: Strategic Partnership Unlocks Nationwide Distribution Network

Gelteq Limited (NASDAQ: GELS) has announced a strategic expansion in North America through an exclusive logistics and distribution agreement with Healthy Extracts (OTCQB: HYEX). Under the partnership, Healthy Extracts will serve as Gelteq's exclusive North American fulfillment partner, managing all product receiving, warehousing, inventory, and order fulfillment from its Henderson, Nevada facility. The collaboration aims to accelerate Gelteq's distribution of gel-based delivery solutions across the United States and Canada while reducing costs and improving operational efficiency. The agreement follows an earlier purchase order from Healthy Extracts for Gelteq products and is expected to enable market distribution by Q3 2025. Both companies anticipate enhanced margin efficiencies, faster delivery times, and new revenue growth opportunities through this vertically aligned partnership.

Evogene 1st-In-Class Model for Generative Molecule Design, Collaboration with Google Cloud

Evogene (NASDAQ: EVGN) has completed version 1.0 of its generative AI foundation model for small molecule design, developed with Google Cloud. The model enhances ChemPass AI's capabilities by simultaneously addressing multiple complex product criteria in pharmaceutical and agricultural applications. The proprietary model achieves 90% precision in novel molecule designs, compared to 29% in traditional GPT AI models, and is built on a dataset of 38 billion molecular structures. The technology enables the creation of potent, synthesizable, and patentable molecules while ensuring strong IP portfolios. Evogene is already developing version 2.0, focusing on enhanced multi-parameter optimization for therapeutic and agricultural applications.

NuCana Melanoma Breakthrough: Key Drug Advances to Expansion Trial, Q1 Loss Drop 63% YoY

NuCana (NASDAQ: NCNA) reported Q1 2025 financial results and provided updates on its cancer drug pipeline. The company's lead program NUC-7738 has shown promising results in treating PD-1 inhibitor-resistant melanoma, leading to an expansion trial with 28 additional patients. NuCana's second program, NUC-3373, is showing positive data in combination with pembrolizumab for advanced solid tumors. The company reported a reduced net loss of £2.5 million in Q1 2025 compared to £6.8 million in Q1 2024. Following a May financing round raising £8.8 million, NuCana's cash position stands at £4.0 million, with runway extended into Q4 2026. Key upcoming milestones include data readouts from both NUC-7738 and NUC-3373 trials, and regulatory guidance from the FDA for NUC-7738's pivotal study in melanoma.